EUVIMEDOpdag EUVIMED
Klinische Studie (Phase II)Multizentrische StudieOpen access

Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity

Huangyang Meng iD, Qianjing Chang, Yashuang Zhang, Jingjing Ren, Hongyu Guo, Liang Yu, Cheng Qian, Yi Jiang, Lin Zhang iD, Wenjun Cheng iD

Science Advances · 2026-04-17 · 12 (16)

DOI: 10.1126/sciadv.aeb0855 ↗

At a glance

Klinische Studie (Phase II) in Science Advances, published on 2026-04-17. Written by Huangyang Meng and 9 co-authors. Institution: Department of Gynecology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu, Nanjing, 210029, China. Major MEDLINE topics: Indoles, Ovarian Neoplasms, Quinolines, Rad51 Recombinase. 46 references. The full text is freely available in PubMed Central. Funded by: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Jiangsu Provincial Key Medical Discipline Fund.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Anlotinib has demonstrated preliminary efficacy as a first-line maintenance therapy for ovarian cancer. However, clinical responses vary widely. To investigate resistance mechanisms and explore rational combinations, pretreatment tumors from 18 patients in clinical trial NCT04807166 underwent whole-exome and RNA sequencing and stratified into sensitive and resistant groups based on progression-free survival. VEGFR-related mutations were enriched in sensitive tumors, whereas resistant tumors showed increased activity of DNA repair pathways and Notch signaling. In vitro screening identified strong synergy between anlotinib and the RAD51 inhibitor RAD51-IN-1, which outperformed the Notch inhibitor FLI-06 in resistant patient-derived organoids. Mechanistic studies revealed that RAD51 inhibition was associated with impaired HRR and increased sensitivity to anlotinib. In vivo, combined treatment with anlotinib and RAD51-IN-1 significantly reduced tumor burden without notable toxicity. These findings suggest that RAD51-mediated HRR may contribute to anlotinib resistance and support RAD51 inhibition as a promising approach to overcome therapeutic resistance in ovarian cancer.

Subjects

MeSH terms (MEDLINE)

IndolesOvarian NeoplasmsQuinolinesRad51 RecombinaseAnimalsFemaleHumansMiceCell Line, TumorDrug Resistance, NeoplasmDrug SynergismGene Expression ProfilingXenograft Model Antitumor Assays

Substances

anlotinibIndolesQuinolinesRad51 Recombinase

Authors and institutions

  • Department of Gynecology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu, Nanjing, 210029, China.
  • Maternal and Child Center Laboratory, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Affiliated Hospital of Nanjing University of Chinese Medicine and China Traditional Chinese Medicine Obstetrics and Gynecology Reproductive Clinical Medicine Innovation Center, Nanjing 210029, China.

ORCID profiles: Huangyang Meng, Lin Zhang, Wenjun Cheng

Funding

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Jiangsu Provincial Key Medical Discipline Fund
  • Jiangsu Province Traditional Chinese Medicine Science and 667 Technology Development Plan Project-Key Project

Cite

APA

Meng, H., Chang, Q., Zhang, Y., Ren, J., Guo, H., Yu, L., Qian, C., Jiang, Y., Zhang, L., & Cheng, W. (2026). Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. Science Advances, 12(16). https://doi.org/10.1126/sciadv.aeb0855

Vancouver

Meng H, Chang Q, Zhang Y, Ren J, Guo H, Yu L, et al. Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. Science Advances. 2026;12(16). doi:10.1126/sciadv.aeb0855

BibTeX
@article{Meng2026,
  author = {Meng, Huangyang and Chang, Qianjing and Zhang, Yashuang and Ren, Jingjing and Guo, Hongyu and Yu, Liang and Qian, Cheng and Jiang, Yi and Zhang, Lin and Cheng, Wenjun},
  title = {Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {16},
  doi = {10.1126/sciadv.aeb0855}
}
Start for free →